热门资讯> 正文
葛兰素史克（GSK）的Jemperli在直肠癌第二阶段试验中实现目标
2026-07-14 07:16
- GSK (GSK) said that interim results from the phase 2 AZER-1 trial showed that patients with a certain type of rectal cancer given Jemperli (dostarlimab) showed a sustained complete clinical response rate at one year.
- Enrolled patients had stage II/III mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer, which represents about 5%-10% of this type of cancer.
- GSK noted that if approved, Jemperli would become the first immunotherapy that could eliminate or delay the use of chemotherapy, radiation, and surgery for this group of rectal cancer patients.
More on GSK
- Is GSK Quietly Becoming An Oncology Powerhouse?
- Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase Inhibitors
- GSK plc (GSK) M&A Call Transcript
- U.S. advises against Congo travel after second American aid worker contracts Ebola
- GSK partner Hansoh posts late-stage trial win for lung cancer drug in China
推荐文章
港股异动 | 保险股普遍走软，友邦保险重挫8%，保诚跌逾5%；据报港险保单收益开征20%个税
摩根大通CEO：金融市场杠杆水平仍高企，隐性借贷可能放大市场动荡
OpenAI披露其智能体“联手越狱”细节 攻破Hugging Face前已协作数月
华盛顿政策不确定性引发担忧 “卖出美国”交易策略争论重燃
华盛早报 | 存储熄火？两大存储巨头闪迪、西数盘后分别大跌8%、12%；突破4200美元阻力位！黄金迎来最佳上涨窗口；泡泡玛特回应段永平持仓下降至5.55%
对冲基金大额阿克曼谈人工智能：SpaceX有点落后，但我不会做空埃隆
上周投下反对票后 卡什卡利再喊加息：美联储应从9月开始行动
财报前瞻 | 存储股“狂欢”继续？闪迪Q4收入料狂增逾340%，三大关键指标值得重点关注
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
